174 related articles for article (PubMed ID: 31473877)
1. The leading established metal-based drugs: a revisitation of their relevant physico-chemical data.
Cirri D; Fabbrini MG; Pratesi A; Ciofi L; Massai L; Marzo T; Messori L
Biometals; 2019 Oct; 32(5):813-817. PubMed ID: 31473877
[TBL] [Abstract][Full Text] [Related]
2. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
3. Metal-N-heterocyclic carbene complexes as anti-tumor agents.
Hu C; Li X; Wang W; Zhang R; Deng L
Curr Med Chem; 2014 Apr; 21(10):1220-30. PubMed ID: 24350852
[TBL] [Abstract][Full Text] [Related]
4. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
Groessl M; Tsybin YO; Hartinger CG; Keppler BK; Dyson PJ
J Biol Inorg Chem; 2010 Jun; 15(5):677-88. PubMed ID: 20213306
[TBL] [Abstract][Full Text] [Related]
6. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
7. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Kenny RG; Marmion CJ
Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
[TBL] [Abstract][Full Text] [Related]
8. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
9. Stimuli-Responsive Therapeutic Metallodrugs.
Wang X; Wang X; Jin S; Muhammad N; Guo Z
Chem Rev; 2019 Jan; 119(2):1138-1192. PubMed ID: 30299085
[TBL] [Abstract][Full Text] [Related]
10. Influence of the Linker Length on the Cytotoxicity of Homobinuclear Ruthenium(II) and Gold(I) Complexes.
Batchelor LK; Păunescu E; Soudani M; Scopelliti R; Dyson PJ
Inorg Chem; 2017 Aug; 56(16):9617-9633. PubMed ID: 28758743
[TBL] [Abstract][Full Text] [Related]
11. RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.
Jain SS; Anderson CM; DiRienzo F; Taylor IR; Jain K; Guha S; Hoque N
Chem Commun (Camb); 2013 Jun; 49(44):5031-3. PubMed ID: 23615723
[TBL] [Abstract][Full Text] [Related]
12. Differences in binding kinetics, bond strength and adduct formation between Pt-based drugs and S- or N-donor groups: A comparative study using mass spectrometry techniques.
Artiaga G; Iglesias-Jiménez A; Moreno-Gordaliza E; Mena ML; Gómez-Gómez MM
Eur J Pharm Sci; 2019 Apr; 132():96-105. PubMed ID: 30844436
[TBL] [Abstract][Full Text] [Related]
13. Noble metal-dithiocarbamates precious allies in the fight against cancer.
Nagy EM; Ronconi L; Nardon C; Fregona D
Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
[TBL] [Abstract][Full Text] [Related]
14. Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.
Machado JF; Correia JDG; Morais TS
Molecules; 2021 May; 26(11):. PubMed ID: 34070457
[TBL] [Abstract][Full Text] [Related]
15. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
16. Intracellular Catalysis with Selected Metal Complexes and Metallic Nanoparticles: Advances toward the Development of Catalytic Metallodrugs.
Soldevila-Barreda JJ; Metzler-Nolte N
Chem Rev; 2019 Jan; 119(2):829-869. PubMed ID: 30618246
[TBL] [Abstract][Full Text] [Related]
17. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.
Ronconi L; Fregona D
Dalton Trans; 2009 Dec; (48):10670-80. PubMed ID: 20023894
[TBL] [Abstract][Full Text] [Related]
18. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
[TBL] [Abstract][Full Text] [Related]
19. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin.
Darabi F; Marzo T; Massai L; Scaletti F; Michelucci E; Messori L
J Inorg Biochem; 2015 Aug; 149():102-7. PubMed ID: 25865000
[TBL] [Abstract][Full Text] [Related]
20. Phosphoroorganic Metal Complexes in Therapeutics.
Demkowicz S; Kozak W; Daśko M; Rachon J
Mini Rev Med Chem; 2016; 16(17):1359-1373. PubMed ID: 27145849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
